Investors sentiment decreased to 1.71 in 2017 Q3. Its down 0.04, from 1.75 in 2017Q2. It dived, as 26 investors sold Amedisys, Inc. shares while 29 reduced holdings. 30 funds opened positions while 64 raised stakes. 31.75 million shares or 5.19% more from 30.18 million shares in 2017Q2 were reported.
Zebra Cap stated it has 0.3% of its portfolio in Amedisys, Inc. (NASDAQ:AMED). Redmile Group Limited Liability Corp holds 283,648 shares. Denver Ltd Company accumulated 8,405 shares or 0.02% of the stock. Credit Suisse Ag invested in 0% or 36,845 shares. Alliancebernstein L P owns 105,558 shares for 0% of their portfolio. New York State Teachers Retirement Systems reported 78,511 shares. Teachers Retirement Sys Of The State Of Kentucky has 0.01% invested in Amedisys, Inc. (NASDAQ:AMED). Voya Inv Ltd Liability holds 0.14% or 1.20 million shares in its portfolio. Amalgamated National Bank & Trust reported 0.01% stake. Rainier Mngmt reported 0.49% stake. Nationwide Fund stated it has 0.03% in Amedisys, Inc. (NASDAQ:AMED). Natixis has 4,460 shares. Ny State Common Retirement Fund stated it has 0% in Amedisys, Inc. (NASDAQ:AMED). 16,092 are held by Fny Managed Accounts Ltd Liability. Walleye Trading Ltd Co reported 0% stake.
Since August 8, 2017, it had 0 buys, and 1 insider sale for $50,000 activity.
The chart of Amedisys, Inc. (AMED) shows a double bottom with $51.30 target or 3.00 % below today’s $52.89 share price. The 7 months chart pattern indicates high risk for the $1.80 billion company. It was reported on Jan, 6 by Finviz.com. If the $51.30 price target is reached, the company will be worth $53.85M less. Double bottoms are rare but powerful chart patterns.
The stock decreased 0.30% or $0.16 during the last trading session, reaching $52.89. About 400,899 shares traded. Amedisys, Inc. (NASDAQ:AMED) has risen 15.02% since January 6, 2017 and is uptrending. It has underperformed by 1.68% the S&P500.
Analysts await Amedisys, Inc. (NASDAQ:AMED) to report earnings on February, 27. They expect $0.59 earnings per share, up 34.09 % or $0.15 from last year’s $0.44 per share. AMED’s profit will be $20.02 million for 22.41 P/E if the $0.59 EPS becomes a reality. After $0.56 actual earnings per share reported by Amedisys, Inc. for the previous quarter, Wall Street now forecasts 5.36 % EPS growth.
Amedisys, Inc. (NASDAQ:AMED) Ratings Coverage
Among 14 analysts covering Amedisys Inc. (NASDAQ:AMED), 6 have Buy rating, 0 Sell and 8 Hold. Therefore 43% are positive. Amedisys Inc. had 36 analyst reports since September 1, 2015 according to SRatingsIntel. The stock of Amedisys, Inc. (NASDAQ:AMED) earned “Hold” rating by Robert W. Baird on Sunday, November 5. The rating was downgraded by Obsidian Research Group on Tuesday, April 5 to “Market Perform”. Mizuho downgraded it to “Neutral” rating and $45 target in Wednesday, November 11 report. The firm has “Neutral” rating given on Wednesday, January 13 by Robert W. Baird. RBC Capital Markets maintained the shares of AMED in report on Monday, July 10 with “Hold” rating. The firm has “Hold” rating by RBC Capital Markets given on Monday, June 5. The stock has “Buy” rating by Oppenheimer on Thursday, July 27. The firm has “Equal-Weight” rating by Stephens given on Friday, June 17. Oppenheimer maintained the shares of AMED in report on Thursday, March 10 with “Outperform” rating. Mizuho maintained Amedisys, Inc. (NASDAQ:AMED) on Wednesday, March 1 with “Neutral” rating.
More notable recent Amedisys, Inc. (NASDAQ:AMED) news were published by: Globenewswire.com which released: “Amedisys Forges Collaborative Partnership with myNEXUS®” on January 04, 2018, also Businesswire.com with their article: “US Post-Acute Care Market 2017-2021 with Kindred Healthcare, Amedisys, LHC …” published on January 04, 2018, Globenewswire.com published: “Amedisys to Present at the 36th Annual JP Morgan Healthcare Conference” on January 05, 2018. More interesting news about Amedisys, Inc. (NASDAQ:AMED) were released by: Seekingalpha.com and their article: “Amedisys, Inc.: Prospects For Future Growth” published on August 05, 2017 as well as Benzinga.com‘s news article titled: “3 Health Care Stocks With M&A Potential In 2018” with publication date: December 22, 2017.